The Dosage of Muscle Relaxants in Morbidly Obese Patients in Daily Practice – A Narrative Review
Paweł Radkowski,Maria Derkaczew,Michał Jacewicz,Dariusz Onichimowski
DOI: https://doi.org/10.2147/ijgm.s474221
IF: 2.145
2024-09-15
International Journal of General Medicine
Abstract:Pawe&lstrok Radkowski, 1– 3 Maria Agnieszka Derkaczew, 2 Micha&lstrok Adam Jacewicz, 4, 5 Dariusz Onichimowski 1, 2 1 Department of Anaesthesiology and Intensive Care, Regional Specialist Hospital in Olsztyn, Olsztyn, Poland; 2 Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum University of Warmia and Mazury in Olsztyn, Olsztyn, Poland; 3 Hospital zum Heiligen Geist, Fritzlar, Germany; 4 Regional Specialist Hospital in Olsztyn, Olsztyn, Poland; 5 Department of Pharmacology and Toxicology, Faculty of Medicine, Collegium Medicum University of Warmia and Mazury in Olsztyn, Olsztyn, Poland Correspondence: Maria Agnieszka Derkaczew, Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum University of Warmia and Mazury in Olsztyn, Olsztyn, Poland, Email The prevalence of morbid obesity in today's population around the world is alarming. Morbid obesity involves substantial changes in body composition and function, which can affect the pharmacodynamics and pharmacokinetics of many drugs. This paper aims to discuss the application of muscle relaxants and their reversing agents in patients with morbid obesity. This work is based both on the available literature and the author's personal experience. Dosage recommendations for muscle relaxants in morbidly obese patients are as follows: non-depolarizing relaxants like rocuronium, vecuronium, atracurium, and cisatracurium should be based on ideal body weight. Succinylcholine dosage should be adjusted to total body weight with a 200 mg maximum, while mivacurium should also be based on total body weight. Pancuronium is not used due to its long duration. Neostigmine dosing remains uncertain, but some suggest using total body weight. When it comes to Sugammadex opinions of the authors are divided, some indicate that it should be dosed based on ideal body weight, but more recent studies show that it should be based on 40% of corrected body weight. Keywords: muscle relaxants, muscle relaxants reversal agents, succinylcholine, sugammadex, morbid obesity, obese patients Obesity is a medical condition characterized by an abnormal and excessive buildup of fat tissue, which can negatively affect health through associated comorbidities. Obesity severity is categorized into three subgroups based on the body mass index (BMI) - moderate obesity with a BMI of 30 to 34.9 kg/m2, severe obesity with a BMI of 35 to 39.9 kg/m2, and morbid obesity with a BMI over 40 kg/m2. Obesity can affect many organs, including the liver and kidneys, and alter the pharmacodynamics and pharmacokinetics of drugs, such as drug metabolism, clearance, distribution, and elimination. 1 Total body weight (TBW) is an actual body weight and can be used to determine the severity of obesity, by comparing it with ideal body weight (IBW) and calculating the percentage increase of TBW from IBW. Obesity starts when TBW exceeds 120% of IBW. Pharmacokinetics describes the connection between the drug dose and its concentration in the blood and pharmacodynamics describes the relationship between the concentration of a drug in an organ and its therapeutic effects. The therapeutic window in obese patients is usually narrower than in healthy subjects. 2 Moreover, morbid obesity can negatively impact respiratory function due to the extra adipose tissue in the chest wall and abdominal cavity, which compresses the thoracic cage, diaphragm, and lungs, leading to changes in lung function, which also can alter the drug elimination. Overdosing of muscle relaxants in obese patients is not uncommon. An anesthesiologist often increases the dose of the muscle relaxant used, aiming to improve the conditions for assisted ventilation, which is actually due to poorer chest wall compliance. 3 Providing adequate skeletal muscle relaxation poses a challenge in patients with advanced obesity. Morbid obesity is associated with significant changes in body composition and function that may alter the pharmacodynamics and pharmacokinetics of muscle relaxants and their reversing agents. Alternative neuromuscular blocking agents like pancuronium, vecuronium, atracurium, and cisatracurium could serve as substitutes for succinylcholine. Nevertheless, these agents exhibit a delayed onset and extended duration of action when administered at standard doses. 4 Rocuronium is one of the most commonly used muscle relaxants in morbidly obese patients nowadays. 5 The ongoing significant issue in dosing medications for obese patients is determining the appropriate weight reference for establishing the precise drug dosage, and this holds for skeletal muscle relaxants as well. 6 The purpose of our study was to pr -Abstract Truncated-
medicine, general & internal